Advances in Radionuclide Imaging
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 3518
Special Issue Editors
2. Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa
Interests: radionuclide imaging; inflammation and infection imaging; cardiovascular inflammation and infection; radionuclide imaging and therapy of thyroid disorders; HIV; tuberculosis; theranostics; prostate cancer
2. Nuclear Medicine Research Infrastructure, Steve Biko Academic Hospital, Pretoria, South Africa
Interests: radionuclide therapy; radiobiology; theranostics; targeted alpha therapy; radionuclide imaging; inflammation and infection imaging; tuberculosis; HIV; fungal infections; prostate cancer; neuroendocrine tumors; novel radiopharmaceutical design; machine learning
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Radionuclide imaging involves the application of radiopharmaceuticals for targeting cellular and subcellular molecular targets expressed in health and diseases. The capability to develop radiopharmaceuticals to examine molecular targets overexpressed in different disease states has contributed tremendously to the versatility of radionuclide imaging. Therefore, in the last decade, there have been tremendous advances in this field, leading to the development of novel radiopharmaceuticals, improvements in click chemistry, allowing for the simplified radiolabelling of many peptides and small molecules for radionuclide imaging within the nuclear medicine department, advances in the technological design of nuclear medicine cameras with consequent improvements in camera performance, improvements in lesion quantification and the broadening of the application of machine learning techniques in nuclear medicine image assessment, and the repurposing of existing radiopharmaceuticals for new indications. These advances have found useful applications, mostly in oncology but also in cardiology, neurology, and inflammation/infection imaging as well. These advances in radionuclide imaging have led to improvements in lesion detection, disease management, early and accurate treatment response assessment, prognostication, and in some instances, cost saving in management. The overall positive impact of radionuclide imaging on patient management has become a driving force in broadening its application in routine clinical practice.
This Special Issue therefore aims to provide a platform for original articles, review articles, opinion pieces, and case reports showcasing recent advances and improvements in current practice and the future direction in radionuclide imaging. We invite authors to submit articles on preclinical, translational, and clinical studies in the following areas: the design and application of novel radiopharmaceuticals, image quantification techniques, the application of machine learning in radionuclide imaging, improvements in lesion detection, new indications for old tracers, image-guided therapy, imaging for the prognostication of therapy outcome, novel insights on current applications of radionuclide imaging, future directions of the application of radionuclide imaging, and improvement in the practice of radionuclide imaging.
Dr. Ismaheel O. Lawal
Prof. Dr. Mike M. Sathekge
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PET/CT
- PET/MR
- SPECT
- radionuclide imaging
- diagnosis
- prognosis of therapy
- image-guided therapy
- oncology
- cardiology
- neurology
- inflammation and infection
- machine learning
- radiopharmaceuticals
- recent advances
- image quantification
